Related Experiment Video
Updated: Aug 29, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
[New drug therapy of chronic obstructive pulmonary disease]
1Division of Medicine, Center for Respiratory Diseases, Mitsui Memorial Hospital.
Abstract:
The progression of chronic obstructive pulmonary disease(COPD) can be inhibited by smoking cessation. As adjunct drugs, nicotine replacement therapy and an antidepressant bupropion are found to improve the abstinence rate from smoking. The mainstay of drug therapy of COPD consists of bronchodilators. Inhaled long-acting anticholinergic agents are in development. Inhaled long-acting beta 2-agonists are newly available. Theophylline has weak antiinflammatory effects. The significance of corticosteroids and mucolytic drugs in stable COPD is yet to be elucidated. In severely hypoxemic patients with COPD long-term domicillary oxygen therapy improves the survival rate. There is no drug therapy which can prevent the long-term deterioration of pulmonary function in patients with COPD. New class of drugs are now in development.
Related Concept Videos
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
COPD: Management Using Bronchodilators and Corticosteroids
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-I: Introduction